ClinicalTrials.gg
CompletedNCT04004221Updated Oct 26, 2024Results posted

Study of Tislelizumab in Participants With Locally Advanced or Metastatic Urothelial Bladder Cancer

A Phase 2 interventional study of Tislelizumab in Locally Advanced or Metastatic Urothelial Bladder Cancer, sponsored by BeiGene. Completed at 27 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-10-26.

Sponsored by BeiGene · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Registered 2 years after the study started (first participant enrolled Jun 2017, registered Jun 2019).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
113
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 194 studies in Urinary Bladder Neoplasms with a site in China — 102 open to participants now, 119 under way, 17 of them phase 3. Urinary Bladder Neoplasms · China.

Enrollment
51st of 141
113 · median 75
Started
2017
with 4 others
Phase 2
40 of 194
22 open now
Registered
30th of 194
by date

Among the 194 studies in Urinary Bladder Neoplasms with a site in China, this one is the 51st largest by enrollment of the 141 interventional ones that give a count, is one of 5 that started in 2017, is one of 40 in phase 2, and was the 30th registered.

Urinary Bladder Neoplasms

1,800 studies on the registry are indexed under Urinary Bladder Neoplasms; 446 are open to participants now.

Browse Urinary Bladder Neoplasms studies →

Open to participants now

102 of the 194 studies in Urinary Bladder Neoplasms with a site in China are open now. Recruiting first, the newest first:

97 more — sign in →

All 102 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 336 Urinary Bladder Neoplasms studies recruiting now, 256 (76%) set no upper age limit and 22 (7%) stop at 75 or younger; 22 take children under 18; 21 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 194 studies in Urinary Bladder Neoplasms with a site in China, or all of them as a file.
02

Study summary

This was a single-arm, multicenter, Phase 2 study to evaluate the efficacy and safety of the anti- programmed cell death-1(PD-1) monoclonal antibody BGB-A317 in participants with PD-L1+, locally advanced or metastatic Urothelial Bladder Cancer (UBC) who have progressed during or following a platinum-containing regimen

03

Conditions studied

  • Locally Advanced or Metastatic Urothelial Bladder Cancer
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  1. Participants with or cytologically documented locally advanced or transitional cell carcinoma (TCC) of the urothelium
  2. Disease progression during or following treatment with at least one platinum-containing regimen for inoperable locally advanced or metastatic urothelial carcinoma or disease recurrence
  3. Participants must submit for determination of program death ligand-1 () expression and other biomarker analyses. PD-L1 expression will be assessed centrally, and participants who are tested as PD-L1 high are eligible.
  4. Participants must have at least one as defined per version 1.1 assessed by the investigator
  5. Male or female, aged ≥18 years on day of signing
  6. Participants have voluntarily agreed to participate by giving written informed consent
  7. (ECOG) performance status of ≤1
  8. ≥12 weeks
  9. Participant must have adequate organ function as indicated by the following screening laboratory values obtained within 7 days prior to the first study treatment

    1. (ANC) ≥1.5×109/L
    2. ≥100×109/L
    3. ≥9 g/dL or ≥5.6 mmol /L (Note: Criteria must be met without a transfusion within 14 days of obtaining the sample)
    4. Calculated ≥ 30 milliliter (mL)/min (Cockcroft-Gault formula, see Appendix 5)
    5. Serum total ≤ 1.5 X (ULN) (total bilirubin must be \<4 X ULN for participants with Gilbert's syndrome)
    6. (AST) and alanine aminotransferase (ALT) ≤ 2.5 X ULN OR ≤ 5 X ULN for participants with liver metastases
  10. Female participants are eligible to enter and participate in the study if they are of:

    1. Non- (ie, physiologically incapable of becoming pregnant), including any female who i) Has had a hysterectomy ii) Has had a bilateral oophorectomy (ovariectomy) iii) Has had a bilateral tubal ligation iv) Is post menopausal (total cessation of menses for ≥1 year)
    2. Childbearing potential, has a negative serum pregnancy test at screening (within 7 days before the first product administration), not be breast feeding, and agree to remain abstinent (refrain from heterosexual intercourse) or uses adequate methods that result in a failure rate of \<1% per year before study entry and throughout the study until 120 days after the last investigational product administration
  11. Male participants are eligible to participate in the study if they are vasectomized or agree to use contraception during the study treatment period and for at least 120 days after the last dose of study drug

Key Exclusion Criteria:

  1. History of severe reactions to other humanized monoclonal antibodies
  2. Prior active within 2 years prior to Cycle 1 Day 1.
  3. Prior therapies targeting PD-1 or PD-L1.
  4. Active brain or as determined by computed tomography (CT) or magnetic resonance imaging (MRI) evaluation during screening and prior radiographic assessments.
  5. Participants with active diseases or history of autoimmune diseases that may relapse should be excluded.
  6. Participants should be excluded if they have conditions requiring systemic treatment with either (>10 mg daily prednisone equivalents) or other medications within 14 days of study drug administration.
  7. Has history of interstitial lung disease or non-infectious pneumonitis except for those induced by radiation therapies
  8. With severe chronic or active infections (including tuberculosis infection, etc) requiring systemic antibacterial, antifungal or antiviral therapy within 14 days prior to first dose of study drug.
  9. With uncontrollable pleural effusion, pericardial effusion or ascites requiring pleurocentesis or abdominal tapping less than 4 weeks
  10. Significant cardiovascular disease, such as (NYHA) cardiac disease (Class II or greater), myocardial infarction within the previous 3 months, unstable arrhythmias, or unstable angina
  11. Known history of (HIV)
  12. Participants with untreated chronic or chronic hepatitis B virus (HBV) carrier with HBV deoxyribonucleic acid (DNA) ≥500 IU/mL (or 2.5 × 103 cps/mL), or active should be excluded. Participant with inactive hepatitis B surface antigen (HBsAg) carrier, active HBV infection with sustained anti-HBV suppression (HBV DNA \<500 IU/mL or 2.5 × 103 cps/mL) and participants whose hepatitis C has been cured (hepatitis C virus [HCV] ribonucleic acid [RNA] is lower than detection limit) can be enrolled
  13. Underlying medical conditions that, in the investigator's opinion, will make the administration of study drug hazardous or obscure the interpretation of toxicity determination or adverse events (AEs)
  14. Prior chemotherapy, radiotherapy, immunotherapy or any investigational therapies (including Chinese herbal medicine and Chinese patent medicines) used to control cancer within 2 weeks of Cycle 1 Day 1. AEs associated with these therapies must be Grade 0-1, baseline or stabilized (except for alopecia)
  15. Prior allogeneic stem cell or solid organ transplant
  16. Administration of a live or attenuated vaccine within 4 weeks prior to study drug administration
  17. Major surgical procedure other than for diagnosis within 28 days prior to study drug administration

NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.

Terms in these criteria, in plain language(29)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
113 participants (actual)

Study arms

  • Experimental
    Tislelizumab

    200mg intravenously (IV) every 3 weeks(Q3W)

    Drug: Tislelizumab

Interventions

  • 200mg intravenously (IV) every 3 weeks (Q3W)

    Also known as: BGB-A317

06

What researchers measure

Primary outcomes

  1. Objective Response Rate (ORR) as Assessed by Independent Review Committee (IRC)

    ORR is defined as the percentage of participants who had confirmed complete response (CR) or partial response (PR) assessed by Independent Review Committee (IRC) using RECIST version 1.1

    Time frame: From the date of first dose up to approximately 2 years and 2 months

Secondary outcomes

  1. Duration of Response (DOR) as Assessed by IRC

    DOR - defined as the time from the first determination of a confirmed objective response by IRC according to RECIST version 1.1 until the first documentation of progression or death, whichever comes first

    Time frame: From the date of first dose up to approximately 2 years and 2 months

  2. Progression-Free Survival (PFS) as Assessed by IRC

    PFS is defined as the time from the date of first dose of study drug to the date of first documentation of disease progression assessed by IRC using RECIST version 1.1 or death, whichever occurs first

    Time frame: From the date of first dose up to approximately 2 years and 2 months

  3. Disease Control Rate (DCR) as Assessed by IRC

    DCR is defined as the percentage of participants who achieve CR, PR and stable disease (SD) assessed by IRC using RECIST version 1.1

    Time frame: From the date of first dose up to approximately 2 years and 2 months

  4. Overall Survival (OS)

    OS - defined as the time from the date of first dose of study drug until the date of death from any cause

    Time frame: From the date of first dose up to approximately 2 years and 2 months

  5. ORR as Assessed by the Investigators

    ORR is defined as the percentage of participants who had confirmed complete response (CR) or partial response (PR) as assessed by the investigators per RECIST version 1.1 and immune related RECIST (irRECIST)

    Time frame: From the date of first dose up to approximately 2 years and 2 months

  6. DOR as Assessed by Investigators Per RECIST Version 1.1 and irRECIST

    DOR is defined as the time from the first determination of a confirmed objective response by the investigator according to RECIST version 1.1 and irRECIST until the first documentation of progression or death, whichever comes first

    Time frame: From the date of first dose up to approximately 2 years and 2 months

  7. PFS as Assessed by Investigators Per RECIST Version 1.1 and irRECIST

    PFS is defined as the time from the date of first dose of study drug to the date of first documentation of disease progression assessed by the investigator according to RECIST version 1.1 and irRECIST until the first documentation of progression or death, whichever comes first

    Time frame: From the date of first dose up to approximately 2 years and 2 months

  8. DCR as Assessed by Investigators Per RECIST Version 1.1 and irRECIST

    DCR is defined as the percentage of participants who achieve CR, PR and stable disease (SD) assessed by investigators per RECIST version 1.1 and irRECIST

    Time frame: From the date of first dose up to approximately 2 years and 2 months

  9. Number of Participants Experiencing Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)

    TEAE is defined as an adverse event (AE) that had an onset date or a worsening in severity from baseline pre-treatment) on or after the first dose of study drug up to 30 days following study drug .discontinuation. An SAE is any untoward medical occurrence that, at any dose that results in death or is life-threatening.

    Time frame: From the date of first dose until End of Study (approximately 3 years and 9 months)

07

Results

Posted Mar 16, 2023

Participant flow

113 participants were enrolled in 27 centers in China and 3 centers in South Korea. All efficacy evaluations were done until 16 September 2019, the primary data cut-off date. Safety evaluations were done until 11 March 2021, the study completion date.

Participant flow — Overall Study
MilestoneTislelizumab
Started113
Completed0
Not completed113
Withdrew: Death89
Withdrew: Withdrawal by subject5
Withdrew: Participants transferred to long-term extension (lte) study9
Withdrew: Sponsor decision9
Withdrew: Participant refused to enter lte1

Outcome measures

PrimaryObjective Response Rate (ORR) as Assessed by Independent Review Committee (IRC)

ORR is defined as the percentage of participants who had confirmed complete response (CR) or partial response (PR) assessed by Independent Review Committee (IRC) using RECIST version 1.1

Time frame:
From the date of first dose up to approximately 2 years and 2 months
Reported as:
Number · Percentage of participants
Objective Response Rate (ORR) as Assessed by Independent Review Committee (IRC)
Percentage of participantsTislelizumab
Objective Response Rate (ORR) as Assessed by Independent Review Committee (IRC)24.0 (16.20 to 33.41)
Statistical analysis
  • Tislelizumab · Exact Binomial Test · p = < 0.00011-sided p-value was based on binomial exact test of Tislelizumab versus historical rate of 0.1
SecondaryDuration of Response (DOR) as Assessed by IRC

DOR - defined as the time from the first determination of a confirmed objective response by IRC according to RECIST version 1.1 until the first documentation of progression or death, whichever comes first

Time frame:
From the date of first dose up to approximately 2 years and 2 months
Reported as:
Median · Months
Duration of Response (DOR) as Assessed by IRC
MonthsTislelizumab
Duration of Response (DOR) as Assessed by IRCNA (8.41 to NA)
SecondaryProgression-Free Survival (PFS) as Assessed by IRC

PFS is defined as the time from the date of first dose of study drug to the date of first documentation of disease progression assessed by IRC using RECIST version 1.1 or death, whichever occurs first

Time frame:
From the date of first dose up to approximately 2 years and 2 months
Reported as:
Median · Months
Progression-Free Survival (PFS) as Assessed by IRC
MonthsTislelizumab
Progression-Free Survival (PFS) as Assessed by IRC2.1 (2.04 to 3.15)
SecondaryDisease Control Rate (DCR) as Assessed by IRC

DCR is defined as the percentage of participants who achieve CR, PR and stable disease (SD) assessed by IRC using RECIST version 1.1

Time frame:
From the date of first dose up to approximately 2 years and 2 months
Reported as:
Number · Percentage of participants
Disease Control Rate (DCR) as Assessed by IRC
Percentage of participantsTislelizumab
Disease Control Rate (DCR) as Assessed by IRC38.5 (29.09 to 48.51)
SecondaryOverall Survival (OS)

OS - defined as the time from the date of first dose of study drug until the date of death from any cause

Time frame:
From the date of first dose up to approximately 2 years and 2 months
Reported as:
Median · Months
Overall Survival (OS)
MonthsTislelizumab
Overall Survival (OS)9.8 (7.46 to 12.48)
SecondaryORR as Assessed by the Investigators

ORR is defined as the percentage of participants who had confirmed complete response (CR) or partial response (PR) as assessed by the investigators per RECIST version 1.1 and immune related RECIST (irRECIST)

Time frame:
From the date of first dose up to approximately 2 years and 2 months
Reported as:
Number · Percentage of participants
ORR as Assessed by the Investigators
Percentage of participantsTislelizumab
RECIST24.0 (16.20 to 33.41)
irRECIST24.0 (16.20 to 33.41)
SecondaryDOR as Assessed by Investigators Per RECIST Version 1.1 and irRECIST

DOR is defined as the time from the first determination of a confirmed objective response by the investigator according to RECIST version 1.1 and irRECIST until the first documentation of progression or death, whichever comes first

Time frame:
From the date of first dose up to approximately 2 years and 2 months
Reported as:
Median · Months
DOR as Assessed by Investigators Per RECIST Version 1.1 and irRECIST
MonthsTislelizumab
RECISTNA (8.31 to NA)
irRECISTNA (8.31 to NA)
SecondaryPFS as Assessed by Investigators Per RECIST Version 1.1 and irRECIST

PFS is defined as the time from the date of first dose of study drug to the date of first documentation of disease progression assessed by the investigator according to RECIST version 1.1 and irRECIST until the first documentation of progression or death, whichever comes first

Time frame:
From the date of first dose up to approximately 2 years and 2 months
Reported as:
Median · Months
PFS as Assessed by Investigators Per RECIST Version 1.1 and irRECIST
MonthsTislelizumab
RECIST2.1 (2.07 to 3.58)
irRECIST2.6 (2.07 to 4.07)
SecondaryDCR as Assessed by Investigators Per RECIST Version 1.1 and irRECIST

DCR is defined as the percentage of participants who achieve CR, PR and stable disease (SD) assessed by investigators per RECIST version 1.1 and irRECIST

Time frame:
From the date of first dose up to approximately 2 years and 2 months
Reported as:
Number · Percentage of participants
DCR as Assessed by Investigators Per RECIST Version 1.1 and irRECIST
Percentage of participantsTislelizumab
RECIST41.3 (31.77 to 51.42)
irRECIST46.2 (36.33 to 56.20)
SecondaryNumber of Participants Experiencing Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)

TEAE is defined as an adverse event (AE) that had an onset date or a worsening in severity from baseline pre-treatment) on or after the first dose of study drug up to 30 days following study drug .discontinuation. An SAE is any untoward medical occurrence that, at any dose that results in death or is life-threatening.

Time frame:
From the date of first dose until End of Study (approximately 3 years and 9 months)
Reported as:
Number · Number of participants
Number of Participants Experiencing Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)
Number of participantsTislelizumab
Participants with At Least 1 TEAE112
Grade 3 or Higher64
Serious TEAEs49

Adverse events

Collected over From the date of first dose until end of study (approximately 3 years and 9 months). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Tislelizumab89/113 (78.8%)49/113 (43.4%)110/113 (97.3%)
Most frequent serious events
Showing 10 of 56
Most frequent serious events
EventTislelizumab
PyrexiaGeneral disorders4/113
PneumoniaInfections and infestations4/113
General physical health deteriorationGeneral disorders3/113
Hepatic failureHepatobiliary disorders3/113
Upper respiratory tract infectionInfections and infestations3/113
Urinary tract infectionInfections and infestations3/113
Drug eruptionSkin and subcutaneous tissue disorders3/113
Decreased appetiteMetabolism and nutrition disorders2/113
HypercalcaemiaMetabolism and nutrition disorders2/113
Cancer painNeoplasms benign, malignant and unspecified (incl cysts and polyps)2/113
Most frequent other events
Showing 10 of 45
Most frequent other events
EventTislelizumab
AnaemiaBlood and lymphatic system disorders44/113
ConstipationGastrointestinal disorders25/113
Urinary tract infectionInfections and infestations23/113
Decreased appetiteMetabolism and nutrition disorders23/113
PruritusSkin and subcutaneous tissue disorders23/113
PyrexiaGeneral disorders22/113
Aspartate aminotransferase increasedInvestigations22/113
HyponatraemiaMetabolism and nutrition disorders21/113
HypoalbuminaemiaMetabolism and nutrition disorders20/113
Alanine aminotransferase increasedInvestigations19/113

Baseline characteristics

Safety Analysis Set includes all participants who received any dose of Tislelizumab

Age, Continuous
Age, Continuous(years)Tislelizumab
Mean62.1 ± 7.85
Sex: Female, Male
Sex: Female, Male(Participants)Tislelizumab
Female29
Male84
Race and Ethnicity Not Collected
Race and Ethnicity Not Collected(Participants)Tislelizumab
Region of Enrollment
Region of Enrollment(participants)Tislelizumab
South Korea5
China108
08

Study locations

27 sites
  • Anhui Provincial Hospital
    Hefei, Anhui 230000, China
  • Peking University Third Hospital
    Beijing, Beijing 100000, China
  • Cancer Hospital Chinese Academy of Medical Sciences
    Beijing, Beijing 100021, China
  • Peking University First Hospital
    Beijing, Beijing 100034, China
  • Peking Union Medical College Hospital
    Beijing, Beijing 100730, China
  • Fujian Medical University Union Hospital
    Fuzhou, Fujian 350001, China
  • The First Affiliated Hospital of Xiamen University
    Xiamen, Fujian 361003, China
  • Sun Yat Sen Memorial Hospital, Sun Yat Sen University (North)
    Guangzhou, Guangdong 510000, China
  • Tongji Hospital of Tongji Medical College Huazhong University of Science and Technology
    Wuhan, Hubei 430030, China
  • Xiangya Hospital of Central South University
    Changsha, Hunan 410008, China
  • Jiangsu Province Cancer Hospital
    Nanjing, Jiangsu 210008, China
  • The First Affiliated Hospital of Nanchang University Branch Donghu
    Nanchang, Jiangxi 330006, China
  • Jiangxi Province Cancer Hospital
    Nanchang, Jiangxi 330029, China
  • The Second Hospital of Dalian Medical University
    Dalian, Liaoning 116023, China
  • The First Hospital of China Medical University
    Shenyang, Liaoning 110001, China
  • Liaoning Cancer Hospital and Institute
    Shenyang, Liaoning 110042, China
  • Fudan University Shanghai Cancer Center
    Shanghai, Shanghai 200000, China
  • Affiliated Zhongshan Hospital of Fudan University
    Shanghai, Shanghai 200032, China
  • Huadong Hospital Affiliated to Fudan University
    Shanghai, Shanghai 200040, China
  • West China Hospital, Sichuan University
    Chengdu, Sichuan 610041, China
  • The Second Affiliated Hospital of Tianjin Medical University
    Tianjin, Tianjin 300000, China
  • Zhejiang Provincial Peoples Hospital
    Hangzhou, Zhejiang 310014, China
  • Zhejiang Cancer Hospital
    Hangzhou, Zhejiang 310022, China
  • The First Provincial Wenzhou Hospital of Zhejiang
    Wenzhou, Zhejiang 325000, China
  • Seoul National University Hospital
    Seoul, Seoul Teugbyeolsi 03080, Korea, Republic of
  • Gangnam Severance Hospital, Yonsei University Health System
    Seoul, Seoul Teugbyeolsi 06273, Korea, Republic of
  • Samsung Medical Center
    Seoul, Seoul Teugbyeolsi 06351, Korea, Republic of
09

References and documents

Publications

  • Ye D, Liu J, Zhou A, Zou Q, Li H, Fu C, Hu H, Huang J, Zhu S, Jin J, Ma L, Guo J, Xiao J, Park SH, Zhang D, Qiu X, Bao Y, Zhang L, Shen W, Bi F. Tislelizumab in Asian patients with previously treated locally advanced or metastatic urothelial carcinoma. Cancer Sci. 2021 Jan;112(1):305-313. doi: 10.1111/cas.14681. Epub 2020 Nov 6. PubMed 33047430 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Upon request, and subject to certain criteria, conditions, and exceptions, BeiGene will provide access to individual de-identified participant data from BeiGene-sponsored global interventional clinical studies conducted for medicines for indications that have been approved or in programmes that have been terminated. BeiGene will also consider requests for the protocol, data dictionary, and statistical analysis plan. Data requests can be submitted to medicalinformation@beigene.com.

Supporting information: Study protocol, Statistical analysis plan

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2017 to primary completion in Sep 2019, 27 months.

Results were first posted in Mar 2023, 3 years 6 months after primary completion.

Of 39 industry-sponsored phase 2 interventional studies under Urinary Bladder Neoplasms, half reached primary completion within 36 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 52. This study's 27 months is below that.

Counting every sponsor, half of 194 studies reached it within 52 months; a quarter within 36 and three quarters within 91.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 28, 2019
First posted
Jul 1, 2019
StartActual
Jun 16, 2017
Primary completionActual
Sep 16, 2019
CompletionActual
Mar 11, 2021
Results first posted
Mar 16, 2023
Last update
Oct 26, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 26, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04004221
Lead sponsor
BeiGene
Responsible party
Sponsor
First posted
Jul 1, 2019
Start date
Jun 16, 2017
Primary completion
Sep 16, 2019
Completion
Mar 11, 2021
Results posted
Mar 16, 2023
Last update
Oct 26, 2024

Study contacts

Study Director
principal investigator · BeiGene

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tislelizumab

Start the discussion